Find out which companies are dominating the industry and how to invest in them. Here are the top 10 CBD oil stocks to buy right now. The FDA’s approval of CBD can change the trajectory of these stocks quickly. If regulators get out of the way, these companies could soar. The rampant growth of the cannabis industry has sparked investor interest in CBD oil stocks. Consider investing in these stocks to grow your portfolio organically.
Best CBD Stocks to Buy: Top Ten Picks
With the growing popularity of medical marijuana across North America, many investors consider investing in stock-exchange listed companies. Investing in CBD stocks is a good idea if you’re looking for an investment with high course potential. Many different companies produce CBD products, and they all have their strengths and weaknesses. As someone who has done extensive research on the best cbd stocks to invest in, I will list my top 10 favorite companies for 2022 listed on NYSE and Nasdaq.
Keep in mind, CDB stocks are currently not in investors focus, and many of them are at longer-term lows right now. It needs to become an attractive investment field with more media dominance again before investments become worthwhile again.
Transparency: We may get compensated when you click on links in this article.
We’ve added current analyst estimates and company fundamentals to each company in the list using the fundamental analysis platform Stock Rover. You can use the free 14-day Stock Rover trial to check the most recent statistics, peers and stock analysis.
What are CBD Oil Stocks
CBD oil stocks refer to companies that produce and distribute CBD products. Companies like these are usually best suited for long-term investments because they have high potential growth over the next decade or more.
What is CDB Oil
CBD oil is a type of natural herb that has been used for many different purposes, including medical and recreational. CBD oils are typically extracted from hemp plants, making them legal in the United States under federal law.
What Brokers to Use to Buy CDB Oil Stocks
The best brokers to buy CDB oil stocks with are either TD Ameritrade or E*TRADE. They’re both straightforward to use and have many great tools that will make investing easier for beginners.
The Best CDB Stocks to Buy
Table of Contents
1. Jazz Pharmaceuticals (JAZZ)
The Ireland-domiciled biopharma company Jazz Pharmaceuticals focuses on treatments for indications in neuroscience, sleeping disorders and hematology-oncology. Jazz Pharmaceuticals still has a negative EPS of -5.46 with a market cap of $10.5 billion. In December 2021, the stock hit a mid-term low at $117.64 and then started a rally to nearly $170 in April 2022.
2. Constellation Brands (STZ)
Cannabis investing ideas also lead to this company with a currently neutral to positive market sentiment. Constellation Brands currently has projected quarterly revenue of 83 million and estimated earnings per share of $1.55.
Constellation Brands is a global leader in beer, wine and spirits with a wide variety of popular brands like Corona Extra and Ballast Point.
Constellation Brands made an investment into Canopy Growth Corporation (WEED) for $191 million worth a few years ago due to the potential growth that cannabis holds. Constellation Brands acquired a 40% ownership stake in Canopy Growth and became the third-largest investor in the cannabis industry. The investments were the right decision, and the stock price went up significantly since.
After forming a mid-term low at $104.28 in March 2020, the price per share increased to a new all-time high in April 2022 at $261.52.
3. AbbVie (ABBV)
AbbVie is a company with a market cap of $200 billion and is a science-led global healthcare company formed in 2013 by the acquisition of Abbott. AbbVie’s product portfolio includes more than 125 products, including pharmaceutical and over-the-counter medications and CBD oil. The stock had a great run from the $60 level in 2000 and market a all-time high in April 2022 at $175.91.
4. Altria (MO)
Altria is a significant producer of tobacco products and has invested in cannabis companies in the past. They have made investments from over $200 million to an equity stake in Cronos Group Inc. a few years back, which is one of the largest Canadian cannabis producers. Not only do they own these stocks, but they also sell cigarettes as well, and the growth potential is enormous. The stock formed a mid-term low at $30.95 in March 2020, and is now trading at $55.23.
5. Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing novel therapeutics to treat rare, chronic inflammatory diseases that are often difficult to treat with existing therapies. CRBP is still Nasdaq listed but might get OTC listed when it remains trading below $1. Right now, the stock is trading at $0.35.
6. Tilray Inc (TLRY)
Tilray is a Canadian company that produces and sells cannabis products, both medical marijuana. They’re best known for being the first company to legally export cannabis from North America for medical purposes through Europe (Greece). The latest news is that they have entered the world of cannabis recreation. The company is focused on research and development, which has allowed them to offer new products like their High CBD Oil Drops for anxiety relief or insomnia issues. They’re also well-known in Canada because all medical marijuana patients are registered with Tilray’s online system called CanvasRx. Many day traders trade Tilray shares due to its high volatile price action during market hours. The price per share is at $5.3 right now.
7. HEXO Corp. Common Shares (HEXO)
HEXO Corp. is a Canadian cannabis company focused on distributing world-class products within the adult-use and medical markets. HEXO Corp. is one of the leading exporters in Canada’s burgeoning cannabis industry to countries around the world where marijuana is legalized for medicinal or recreational purposes. Like CRBP, the stock is trading below $1 for a while (at $0.41 right now) and might get delisted from Nasdaq.
8. Cronos Group Inc. (CRON)
Cronos Group Inc. is a company focused on medical marijuana and recreational cannabis for adult use. They’re best known for producing, selling, and marketing products in Canada, Germany, Israel, Italy and Australia. Cronos Group announced that they were partnering with Ginkgo Bioworks to engineer yeast that produces cannabinoids genetically. The good thing with Cronos is that they have a lot of room to grow based on solid company fundamentals. Right now, the stock is trading at $3.08.
9. Aurora Cannabis (ACB)
Aurora Cannabis is a Canadian company that is a producer and seller of medical cannabis products. They’re best known for being the first marijuana company to be listed on an American stock exchange. Recently Aurora Cannabis announced that they were entering the European market by acquiring a German company. The stock is currently trading at $3.1. They recently had a formal bid accepted and are set to acquire CanniMed Therapeutics, which has experts speculating that the company could be worth $600 million. Aurora is one of those stocks best to buy because it’s still undervalued due to its marijuana production being in Canada. Still, they have made their intentions known for expansion into Europe unfolding additional potential.
10. ETFMG Alternative Harvest ETF (MJ)
You have already read about the top favorite CBD stocks to buy. Investors can also participate in CBD oil stock growth by buying the exchange-traded fund. The ETFMG Alternative Harvest ETF is a fund that invests in companies operating in the global cannabis industry. The ETFMG Alternative Harvest ETF is an umbrella term as it includes a variety of sectors. The ETF is currently trading at an 5-year low at $8.45.
Introduction to Marijuana Stocks
Marijuana stocks are made up to become a thriving and profitable industry. With the legalization of cannabis in Canada and previously in the United States, stocks are bound to arise.
Cannabis companies are not only for those in North America but all over the world, from Europe to Africa. Cannabis stocks are an opportunity that investors can’t afford to miss out on now! One of the best next best things in speculative investing is CBD oil stocks and similar companies. With marijuana becoming more mainstream, there will be a rise of people looking to invest in this sector.
Marijuana Stocks With the Most Momentum
Momentum investing is when you invest in stocks that have gone up faster than the market. If a stock has risen more than the market, momentum investors think it will continue to do so because of factors that caused it to go up. Investors want to buy stocks with high returns and count on a trend continuation in the subsequent months for the stock. The concept is to analyze data of potential Marijuana stocks to buy via Nasdaq, NYSE or even OTC. While investments in ETFs are often compound profits over the years by contribution to the ETFs, specific investing in Marijuana momentum stocks aim for short-term growth with higher risk and higher potential. Keeping an eye on company financials, earnings, cannabis use, and news is important too.
The Role of the Farm Bill
The farm bill was passed to legalize the production and sale of hemp. This is a major step in the right direction for marijuana stocks and will help make it more mainstream and provide employment opportunities with its legalization. The best thing about investing in cannabis companies is that you can get an ownership stake through stock buybacks or dividends.
How to Gain Access to the Global Cannabis Stock Market
An online broker allows you to invest in marijuana stocks from around the world. It is a great way to diversify your portfolio, find new opportunities, and provide liquidity for international investments. By doing this, you can also invest in companies involved with CBD oil processing and production.
Conclusion About the Best CBD Stocks to Buy
Marijuana stocks are a great way to diversify your portfolio and find new opportunities. Investing in them provides liquidity for international investments and owning an ownership stake through stock buybacks or dividends.
Cbd stocks are a wise investment choice that is forecasted to grow exponentially in the future. The product development recently has resulted in a massive uptick in the interest of CBD stocks, and as such, it is crucial to stay up-to-date with this market.
The best CBD stocks have shown strong revenue growth over the past five years and are positioned for rapid future growth due to their product development. The earnings per share are solid for many companies in the marijuana industry, and more and more brands enter the profitable cannabis market.
It is essential to diversify your portfolio, so it is wise to invest in a range of stocks. Marijuana-focused companies with solid fundamentals, which will allow investors the best returns for their investment at a reasonable stock price, are a good starting point.
About the author: Alexander is the founder of daytradingz.com and has 20 years of experience in the financial markets. He aims to make trading and investing easy to understand for everybody, and has been quoted on Benzinga, Business Insider and GOBankingRates.
Top Three CBD Stocks to Watch Closely in 2022
There’s a lot of overlap between CBD stocks and pot stocks. Which, of course, makes perfect sense. The cannabis plant has scores of active chemical compounds in it. One of them is delta-9-tetrahydrocannabinol (THC). This is the compound that gets stoners… stoned.
The other big one is cannabidiol (CBD). This compound has no psychoactive properties. But there are a whole lot of potential health benefits. Now, marijuana producers have no need to weed out the CBD. However, companies focusing on CBD do have to keep out the THC if they want to sell their products over the counter. But it’s not terribly difficult if the CBD is derived from industrial hemp. Which, unlike marijuana, is not a controlled substance.
To complicate matters even further, the Food & Drug Administration (FDA) hasn’t compiled a lot of information on CBD. So, it lingers in a state of near-limbo… due, if nothing else, to its close proximity to THC. It’s not quite legal. But based on how easy it is to find CBD products at the local pharmacy, grocery store and coffee shop; it’s obviously not illegal either. However, its legal status can depend on which state you live in.
Here’s how that works…
In 2018, President Trump signed the Agriculture Improvement Act. This is better known as the 2018 Farm Bill. In that act, there was a section that removed hemp from the Controlled Substances Act. Thanks to that bill, CBD – which can be extracted from hemp – was deemed legal on the federal level. The bill targeted the agricultural aspect, though. Compounds extracted from hemp – à la CBD – aren’t privy to the same complete green light as hemp itself. So CBD operates in a mixed jurisdictional realm.
Warning: More Politics & Science Ahead
The federal government won’t arrest folks for growing hemp anymore. Extracting CBD or possessing it isn’t a federal crime anymore either. Well, if there’s less than 0.3% THC content. But not all states see eye to eye with the feds. Some states still want to see more evidence of the benefits and lack of drawbacks. And in some states, CBD remains blacklisted.
But here’s a big feather in the cap of CBD. The Food & Drug Administration has approved a CBD product to treat Lennox-Gastaut syndrome. It’s also been approved to treat Dravet syndrome. To paraphrase, it’s been proven to help those suffering from certain types of epilepsy.
When Greenwich Biosciences received approval for its epilepsy drug, Epidiolex, it was initially considered a controlled substance. Simply because it was derived from marijuana. But when the company requested it be removed from the controlled substances list, the Drug Enforcement Agency (DEA) agreed. This was a big deal because it was the first time the DEA removed any type of cannabis compound from Schedule 1. And this could eventually prove to be a tipping point.
Regardless of what the FDA says, studies have shown that CBD can help to treat insomnia and anxiety. And it can even act as an antidepressant. It has also helped those dealing with chemotherapy and can treat acne. Nonetheless, not everyone remains sold on the prospect of CBD. And at least part of the problem is bad actors.
The FDA had to warn folks to stop claiming CBD could cure the coronavirus. Also, it probably can’t fix “dryness and frizz” in hair or prevent it from turning gray. That’s the kind of claim the FDA is looking out for. And more importantly, we know at this point that it can do some positive things. And here are three companies proving it…
Three CBD Stocks Worth Investing In
- GW Pharmaceuticals (Nasdaq: GWPH)
- Charlotte’s Web Holdings (OTC: CWBHF)
- CV Sciences (OTC: CVSI)
We’ll start with the big one. GW has essentially built its future and reputation on prescription CBD products. It’s the parent company of Greenwich Biosciences – the maker of Epidiolex. It has also received approval of its Sativex therapy in several countries. It’s a multiple sclerosis treatment that is a cannabis-extracted spray containing CBD. It’s used to treat multiple sclerosis.
Even right now, as some of its therapies remain in limbo, GW stock is pricey. But it’s proven to be insulted from the price swings of the marijuana market. The company also has an impressive pipeline of therapies in the works. And approval of them could send this CBD stock skyrocketing.
Charlotte’s Web Holdings
Charlotte’s Web Holdings can be viewed as the indicator of the CBD industry. If CBD sales are on the rise, this CBD stock will be one of the first to indicate it.
The company recently acquired the topical treatment manufacturer Abacus Health Products with the intention of expanding its product line. The plans have already paid off, with net revenue up 1% in 2021. And increasing product lines should only further help the company’s bottom line. This Colorado-based company has deals with major retailers, including Kroger (NYSE: KR), The Vitamin Shoppe and CVS (NYSE: CVS). Once the FDA clears up the regulatory uncertainty surrounding CBD food products, you can expect this stock to soar.
This company has two distinct segments: consumer products and drug development. The consumer products one is straightforward. It focuses on manufacturing, marketing and selling CBD products. On the other hand, the pharmaceutical division is constantly trying to push the needle and develop novel CBD-based therapeutics. But the company already has the top-selling hemp-derived CBD oil on the market.
CV Sciences’ PlusCBD Oil was the first supplement to receive “generally recognized as safe” (GRAS) status. And the company continues to grow its product line. The company is currently developing synthetic CBD-based medicine and is pursuing FDA approval for drugs. But again, once regulations around CBD are relaxed, this CBD stock is expected to see a major bounce.
The Bottom Line on CBD Stocks
Bills have been introduced to amend the Federal Food, Drug and Cosmetic Act and its regulations of hemp-derived CBD. The best guess as to why they haven’t moved forward is that Congress got distracted by the pandemic. But they should be picked up again. If the FDA finally gets out of the way, these CBD stocks are going to be major beneficiaries.
Unfortunately, for now the prospects of this budding industry are still tied up in politics. And the FDA’s approval (or lack thereof) can change the trajectory of these stocks quickly.
About Matthew Makowski
Matthew Makowski is a senior research analyst and writer at Investment U. He has been studying and writing about the markets for 20 years. Equally comfortable identifying value stocks as he is discounts in the crypto markets, Matthew began mining Bitcoin in 2011 and has since honed his focus on the cryptocurrency markets as a whole. He is a graduate of Rutgers University and lives in Colorado with his dogs Dorito and Pretzel.
Best CBD Oil Stocks
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world’s largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company’s Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%). They are considered a leader in the cannabis and tobacco industry.
|Day Range 45.04 – 45.86||52 Wk Range 41 – 57.05||Open / Close 45.24 / 45.57||Float / Outstanding – / 1.8B|
|Vol / Avg. 7.8M / 10.6M||Mkt Cap 82.1B||P/E 46.07||50d Avg. Price 43.93|
|Div / Yield 3.76/8.33%||Payout Ratio 367.35||Total Float –||EPS –|
Jazz Pharmaceuticals ( XNAS: JAZZ )
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz’s product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.
|Day Range 151.99 – 154.29||52 Wk Range 126.14 – 169.98||Open / Close 152.11 / 152.66||Float / Outstanding – / 62.7M|
|Vol / Avg. 374.6K / 488.3K||Mkt Cap 9.6B||P/E –||50d Avg. Price 156.18|
|Div / Yield –||Payout Ratio –||Total Float –||EPS –|
Village Farms Intl ( XNAS: VFF )
As one of the largest and longest-operating greenhouse growers in North America, Village Farms International produces and distributes premium cannabis to national growers in the U.S. and Canada.
The cannabis stock has a market cap of $288 million and trades over 1 million shares per day. It has an EPS of $0.04 and a P/E ratio of 128. Village Farms International generated total revenue of $144 million in 2019, making it one of the best stocks under $10.
Village Farm International recently reported its revenue in Q1 2020 and declared that it has had a profitable business for the 5th consecutive quarter. The cannabis company has also announced that it has expanded its credit facility with its existing lender by $59 million.
|Day Range 2.51 – 2.62||52 Wk Range 2.44 – 7.22||Open / Close 2.51 / 2.57||Float / Outstanding – / 88.6M|
|Vol / Avg. 639.5K / 680.7K||Mkt Cap 227.6M||P/E –||50d Avg. Price 2.84|
|Div / Yield –||Payout Ratio –||Total Float –||EPS –|
GrowGeneration ( XNAS: GRWG )
GrowGeneration Corp. is a premier supplier of cannabis and cannabis-growing equipment. These products include organic nutrients, drip systems, water pumps, air pumps, LED lights and commercial light systems. It is the largest hydroponic supplier in the U.S., with 31 retail and distribution centers.
The cannabis stock has a market cap of $849 million and has an EPS of $0.02. It has an annual dividend yield of $0.02 per share. GrowGeneration has high liquidity and trades more than 1.7 million shares per day. It generated revenue of $79 million in 2019.
|Day Range 4.55 – 4.79||52 Wk Range 3.42 – 14.1||Open / Close 4.58 / 4.72||Float / Outstanding – / 60.8M|
|Vol / Avg. 730.4K / 1.4M||Mkt Cap 286.9M||P/E –||50d Avg. Price 4.76|
|Div / Yield –||Payout Ratio –||Total Float –||EPS –|
AbbVie ( XNYS: ABBV )
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The company’s top drug, Humira, represents close to half of the company’s current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women’s health.
|Day Range 140.1 – 142.17||52 Wk Range 128.26 – 175.91||Open / Close 140.4 / 141.42||Float / Outstanding – / 1.8B|
|Vol / Avg. 4.4M / 5.5M||Mkt Cap 250B||P/E 19.88||50d Avg. Price 144.55|
|Div / Yield 5.64/4.01%||Payout Ratio 76.66||Total Float –||EPS –|
After the legalization of marijuana in the U.S., many companies are actively engaged in the research, development and distribution of cannabis. Cannabidiol (CBD) is the non-psychoactive substance present within cannabis and its products such as CBD oil has had a major impact on the health and wellness industry.
Take a look at these CBD oil stocks that are generating millions of dollars in revenue this year.
Overview: CBD Oil Stocks
Since ancient times, cannabis has been used as a form of medicine and as a means to induce euphoria. Indian sages have also mentioned the medicinal use of marijuana in Vedic hymns of antiquity.
However, President Richard Nixon banned the cultivation and sale of marijuana in the U.S. as part of his “war on drugs” campaign in 1970. It wasn’t until the Compassionate Use Act of 1996 was passed that California became the first state to legalize marijuana to treat people with severe or chronic diseases. As of 2022, 37 states in the U.S. have legalized the medical use of marijuana and 18 states have legalized the recreational use of marijuana.
According to a recent report by the New Frontier Data, the legal sale of cannabis could reach $30 billion by 2025. Due to such high potential to earn profits, alcohol companies have started to invest big in CBD oil companies.
Constellation Brands Inc. (NYSE: STZ) has invested billions in Canopy Growth Corp. (NYSE: CGC). Molson Coors (NYSE: TAP) invested billions in Hexo (TSX: HEXO). Budweiser (NYSE: BUD) entered a joint venture to develop non-alcoholic CBD drinks with Tilray Inc. (NASDAQ: TLRY).
You can still catch up with the market trend and gain some good earnings by investing in CBD oil stocks today.
Best Online Brokers for CBD Oil Stock
Online brokers let you browse and trade thousands of stocks listed on major stock exchanges. These platforms are bundled with tons of educational resources and tools to let you manage your stock portfolio on the go. Many of these online brokers also allow you to trade stocks commission-free.